{"disease":{"id":"blasts-5-percent-or-more-of-bone-marrow-nucleated-cells","name":"blasts 5 percent or more of bone marrow nucleated cells"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03698552","title":"ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":37,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02529813","title":"CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03519984","title":"EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT03851081","title":"Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}